National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Empagliflozin (Jardiance®). HTA ID: 21030

Empagliflozin (Jardiance®) is indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

 

NCPE Assessment Process Complete
Rapid review commissioned 05/07/2021
Rapid review completed 29/07/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of empagliflozin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/08/2021
Pre-submission consultation with Applicant 18/10/2021
Full submission received from Applicant 12/01/2022
Preliminary Review sent to Applicant 28/02/2022
NCPE assessment re-commenced 28/03/2022
Factual Accuracy Check sent to Applicant 30/03/2022
NCPE assessment re-commenced 07/04/2022
NCPE assessment completed 28/04/2022
NCPE assessment outcome

The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.